Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Bluewillow Biologics Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 3 distinct examiners, each operating within 3 distinct art units. This level of distribution across 3 distinct art units indicates that the company's pending applications fall under different examination specialties. Having every action in a different unit shows the technological footprint for the company within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for the portfolio is CHHAY, BONIRATH, who is currently managing 1 pending office action. Since there are 3 pending actions and 3 distinct examiners, each examiner is responsible for 1 of the active matters. This structure means the company must coordinate its prosecution strategy across 3 different administrative groups. Managing 3 pending office actions under these conditions requires the applicant to address the unique prior art and legal hurdles presented by 3 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHHAY, BONIRATH | 1 | 83.3% | +0.0% |
| HILL, MYRON G | 1 | 66.2% | +20.6% |
| BERRIOS, JENNIFER A | 1 | 37.0% | +49.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724898 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | CHHAY, BONIRATH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17292714 | NANOEMULSION COMPOSITIONS HAVING ENHANCED PERMEABILITY | BERRIOS, JENNIFER A | 20d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17292714 | NANOEMULSION COMPOSITIONS HAVING ENHANCED PERMEABILITY | BERRIOS, JENNIFER A | 20d |
| 17503575 | HERPES SIMPLEX VIRUS NANOEMULSION VACCINES AND METHODS OF USING THE SAME | HILL, MYRON G | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1671 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724898 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | CHHAY, BONIRATH | 1645 | §103§112DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 17503575 | HERPES SIMPLEX VIRUS NANOEMULSION VACCINES AND METHODS OF USING THE SAME | HILL, MYRON G | 1671 | §112DP | Final Rejection | — | Pending | Oct 18, 2021 |
| 17292714 | NANOEMULSION COMPOSITIONS HAVING ENHANCED PERMEABILITY | BERRIOS, JENNIFER A | 1613 | §103§112 | Final Rejection | 20d | Pending | May 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial